1. Scrip
  2. >>Conferences
  3. >>BIO

Competitive Dealmaking Market Shifts To Smaller M&A, Partnering

Acquisition Numbers Rise, Values Fall In Q1

 
• By Mandy Jackson

Dollars spent on biopharma M&A so far in 2024 may not be as high as in 2023, but dealmakers say deal volume is robust with many factors influencing the overall value of transactions this year.

Multiple stock graphs and numerical data overlaid on a cityscape, representing the finance and economy
Deals are happening, but they are not as large as in 2023 • Source: Shutterstock

Business development executives on site at this year’s BIO International Convention in San Diego noted that while the total dollar value of deals announced so far in 2024 may not be as high as it was at mid-year in 2023, negotiations for new partnerships and M&A are keeping dealmakers busy.

Key Takeaways

  • Business development executives and investors at the BIO International Convention said that biopharma dealmaking activity in 2024 is robust despite shifts in focus for big pharma.

Biomedtracker reported 39 M&A deals totaling $37bn during the first quarter of 2024, an improvement in terms of the number...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from BIO

AI Is Inevitable, But Useful Only If Solves The Right Problems

 
• By Mandy Jackson

Scrip spoke with executives at artificial intelligence biotech firms and a big pharma company during the recent BIO conference about using AI in ways that add real value to drug development.

BIO China Deal Perspectives: A Dramatic Impact On Industry’s R&D Pipelines

 
• By Mandy Jackson

Biopharma executives and investors at the BIO convention noted the competition emerging from China with high-quality assets that could make strong additions to their portfolios.

BIO Finance Trends: Drug Developers Face Harsh Realities As Funding Constraints Continue

 
• By Mandy Jackson

Financial markets were expected to loosen up in 2025, but BIO convention attendees indicated that conditions have worsened this year, so public and private firms are making tough choices.

Post-BIO Podcast: Thoughts From The Frontlines

 
• By Sarah Karlin-Smith, Mandy Jackson, and Mary Jo Laffler

Scrip and Pink Sheet journalists reflect on the mood from Boston, the most important takeaways and what’s next for industry.

More from Conferences

Post-BIO Podcast: Thoughts From The Frontlines

 
• By Sarah Karlin-Smith, Mandy Jackson, and Mary Jo Laffler

Scrip and Pink Sheet journalists reflect on the mood from Boston, the most important takeaways and what’s next for industry.

BIO Deal Trends: Financial Market Stress Creates Transactional Opportunities

 
• By Mandy Jackson

M&A may not be booming in 2025, but BIO convention attendees reported no shortage of potential deals, especially as cash-strapped drug developers seek funding alternatives.

Chinese Developers Showcase Potentially Differentiated Weight Loss Assets At ADA

 
• By Xu Hu

Multiple Chinese firms presented at this year’s ADA meeting, with a focus on weight reduction efficacy for mostly early clinical stage assets. While limited information was given on lean mass preservation, several companies are progressing drugs and combos to address this need.